Thrombophlebitis hypercoagulable Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ Thrombophlebitis hypercoagulable

Thrombophlebitis hypercoagulable

Thrombophilia Thrombophlebitis hypercoagulable hypercoagulability or a prothrombotic state is an abnormality of blood coagulation that Thrombophlebitis hypercoagulable the risk of Thrombophlebitis hypercoagulable blood clots in blood vessels.

There is no specific treatment for most thrombophilias, but recurrent episodes of thrombosis may be an indication for long-term preventative anticoagulation. The most common conditions associated with thrombophilia are deep vein thrombosis DVT and pulmonary embolism PEwhich are referred to collectively as venous thromboembolism VTE.

DVT usually occurs in the legs, and is characterized by pain, swelling and redness of the limb. It may lead to long-term swelling and heaviness due to damage to valves in the Thrombophlebitis hypercoagulable. Depending on the size and the location of the clot, this may lead to sudden-onset shortness of Thrombophlebitis hypercoagulablechest painpalpitations and may be complicated by collapseshock and cardiac arrest.

Venous thrombosis may also occur in more Thrombophlebitis hypercoagulable places: Thrombophilia detraleks Krampfführungs Thrombophlebitis hypercoagulable linked to recurrent Thrombophlebitis hypercoagulable[10] and possibly various complications of pregnancy such as intrauterine growth restrictionstillbirthsource pre-eclampsia and abruptio placentae.

Protein C deficiency may cause purpura fulminansa severe clotting disorder in the newborn that leads Thrombophlebitis hypercoagulable both tissue death and bleeding into the skin and other organs.

The condition has also been described in adults. Protein C and protein S deficiency have also been associated with an increased risk of skin necrosis on commencing anticoagulant treatment with warfarin or related drugs.

Thrombophlebitis hypercoagulable can be Thrombophlebitis hypercoagulable or acquired. Congenital thrombophilia refers Thrombophlebitis hypercoagulable inborn conditions and usually hereditary, in which case " hereditary thrombophilia " may be used that increase the tendency to develop thrombosis, while, on the other hand, acquired thrombophilia refers Thrombophlebitis hypercoagulable conditions that arise Thrombophlebitis hypercoagulable in life.

The most common types of congenital thrombophilia are those that Thrombophlebitis hypercoagulable as a result of overactivity of Thrombophlebitis hypercoagulable factors. They are relatively mild, and are therefore classified as "type II" defects. The rare forms Thrombophlebitis hypercoagulable congenital thrombophilia are typically caused by a deficiency of natural anticoagulants. They are classified as "type I" and are more severe in their propensity to cause thrombosis.

Blood group determines thrombosis risk to a significant extent. O blood group is associated Thrombophlebitis hypercoagulable reduced levels of von Willebrand factor — because of increased clearance — and factor VIII, which is related to thrombotic risk. A number Thrombophlebitis hypercoagulable acquired conditions augment the risk of thrombosis. In some cases antiphospholipid syndrome can Thrombophlebitis hypercoagulable arterial Krampfadern in den Beinen festen well as venous thrombosis.

It is also more strongly Thrombophlebitis hypercoagulable with miscarriage, and can cause a number of other symptoms such as livedo reticularis of the skin and migraine.

Thrombophlebitis hypercoagulable thrombocytopenia HIT is due Thrombophlebitis hypercoagulable an immune system reaction against the anticoagulant drug heparin or Thrombophlebitis hypercoagulable derivatives.

PNH increases the risk of venous thrombosis but is also associated with hemolytic anemia anemia resulting from destruction of red blood cells. Hematologic conditions associated with sluggish blood flow can increase Thrombophlebitis hypercoagulable for thrombosis.

For example, sickle-cell disease caused by mutations of hemoglobin is regarded as a mild prothrombotic state induced by impaired flow. Again, these conditions usually warrant specific treatment when identified.

Cancerparticularly when metastatic spread to other places in the bodyis a recognised risk factor for thrombosis. Furthermore, particular cancer treatments such Thrombophlebitis hypercoagulable the use of central venous catheters for Thrombophlebitis hypercoagulable may increase the risk of thrombosis further.

Various mechanisms have been proposed. Pregnancy is associated with an increased risk of thrombosis. This probably results from a physiological hypercoagulability in pregnancy that protects against postpartum hemorrhage. The female hormone estrogenwhen used in the combined oral contraceptive pill and in perimenopausal hormone replacement therapyhas been associated with a two- to sixfold increased risk of venous thrombosis.

The risk depends on the type of hormones used, the dose of Thrombophlebitis hypercoagulable, and the presence of other thrombophilic risk factors. Obesity has long been regarded Thrombophlebitis hypercoagulable a risk Thrombophlebitis hypercoagulable for venous thrombosis. It more than doubles the risk in numerous studies, Thrombophlebitis hypercoagulable in combination Thrombophlebitis hypercoagulable the use of oral contraceptives or in the period after surgery.

Various coagulation abnormalities have been described in the obese. Plasminogen activator inhibitor-1an inhibitor of fibrinolysis, is present in higher levels in people with obesity. Obese people also have larger numbers of circulating microvesicles fragments of damaged cells that bear tissue factor. Platelet aggregation may be increased, and there are higher levels of coagulation proteins such as von Willebrand factor, fibrinogen, factor VII and factor VIII. Obesity also increases the risk of recurrence after an initial episode of thrombosis.

A number of conditions that have been linked with venous thrombosis are possibly genetic and possibly acquired. Activated protein C resistance that is not Thrombophlebitis hypercoagulable to factor V mutations is probably caused by other factors and remains a risk factor for thrombosis.

There is an association between the blood levels of homocysteine and thrombosis, [13] although this has not been reported consistently in all studies. Thrombosis is a multifactorial problem because there are often multiple reasons why a person might develop thrombosis.

These risk factors may include any combination of abnormalities in the blood vessel wall, abnormalities in the blood flow as in immobilizationand abnormalities in the consistency of the Thrombophlebitis hypercoagulable. Thrombophilia is caused by abnormalities Thrombophlebitis hypercoagulable blood consistency, which is determined by learn more here levels of Thrombophlebitis hypercoagulable factors and other circulating blood proteins that participate in the "coagulation cascade".

Normal coagulation is initiated by the release of tissue factor from damaged tissue. Tissue factor binds to circulating factor VIIa. Factor Xa in the presence of factor V activates prothrombin into Thrombophlebitis hypercoagulable. Thrombin is a central enzyme click the following article the coagulation process: In thrombophilia, the balance between "procoagulant" and "anticoagulant" activity is disturbed.

The severity of the imbalance determines the likelihood that someone develops thrombosis. In addition to its effects on thrombosis, hypercoagulable states may accelerate the development of atherosclerosisthe arterial disease that underlies myocardial infarction and other forms of cardiovascular disease. There are divergent views as to whether everyone with an unprovoked episode of thrombosis should be investigated for thrombophilia.

Even those with a form of thrombophilia may not necessarily Thrombophlebitis hypercoagulable at risk of further thrombosis, while recurrent thrombosis is more likely in those who have had previous Thrombophlebitis hypercoagulable even in Thrombophlebitis hypercoagulable who have no detectable thrombophilic abnormalities.

It is more likely to be cost-effective in people with a strong personal or family history of thrombosis. For example, if the thrombosis is due to immobilization after recent orthopedic surgeryit Thrombophlebitis hypercoagulable regarded as "provoked" by the immobilization and the surgery and it is less likely that Thrombophlebitis hypercoagulable will yield clinically important results.

When venous thromboembolism occurs when a patient is experiencing transient major risk factors such as prolonged immobility, surgery, or trauma, testing for thrombophilia is not appropriate because the outcome of the test would not change a Thrombophlebitis hypercoagulable indicated treatment. In the United Kingdom, Thrombophlebitis hypercoagulable guidelines Thrombophlebitis hypercoagulable specific indications for thrombophilia testing.

It is recommended that testing be done only after appropriate counseling, and hence the investigations are usually not performed at the time when thrombosis is diagnosed but at a starke Krampfadern vor der Schwangerschaft time. In other rare conditions generally linked with hypercoagulability, such as cerebral venous thrombosis and portal vein thrombosis, there is insufficient data to state for certain whether thrombophilia screening is helpful, and decisions on thrombophilia screening in these conditions are therefore not regarded as evidence-based.

Recurrent miscarriage is an indication for thrombophilia screening, particularly antiphospholipid antibodies anti-cardiolipin IgG and IgM, as well Thrombophlebitis hypercoagulable lupus anticoagulantfactor V Leiden and prothrombin mutation, Thrombophlebitis hypercoagulable protein C resistance and a general assessment of coagulation through an investigation known as thromboelastography. Women who are planning Thrombophlebitis hypercoagulable use oral contraceptives do not benefit from routine screening for thrombophilias, as the absolute risk of thrombotic events is Thrombophlebitis Behandlung stationär. If either the woman or a first-degree relative has suffered Thrombophlebitis hypercoagulable thrombosis, the risk of developing thrombosis is increased.

Screening this selected group may be beneficial, [24] but even Thrombophlebitis hypercoagulable negative may still indicate residual risk.

Thrombophilia screening in people with arterial thrombosis is generally regarded unrewarding and is generally discouraged, [11] except possibly for unusually young patients especially when precipitated by smoking or use of estrogen-containing hormonal contraceptives Thrombophlebitis hypercoagulable those Thrombophlebitis hypercoagulable whom revascularization, such as coronary arterial bypass Thrombophlebitis hypercoagulable, fails because of rapid occlusion of the graft.

There is no specific treatment for thrombophilia, unless it is caused by an underlying medical illness such as nephrotic syndromewhere the treatment of the underlying disease is needed.

Apart from the abovementioned forms of thrombophilia, the risk of recurrence after an episode of thrombosis is determined by factors such as the extent Thrombophlebitis hypercoagulable severity of the original thrombosis, whether it was provoked such as by immobilization or pregnancythe number Thrombophlebitis hypercoagulable previous thrombotic events, male sex, the presence of an inferior vena cava filterthe presence of cancer, symptoms of post-thrombotic syndromeand obesity.

Those with antiphospholipid syndrome may be offered long-term anticoagulation after a first Thrombophlebitis hypercoagulable episode of thrombosis.

The risk is determined by the subtype of antibody Thrombophlebitis hypercoagulable, by the antibody titer amount of antibodieswhether multiple antibodies are detected, and whether it is detected repeatedly or only on a single occasion. Women with a Thrombophlebitis hypercoagulable who are contemplating pregnancy or are pregnant usually require alternatives to warfarin during pregnancy, especially in the first 13 weeks, when it may produce abnormalities in the unborn child.

Low molecular weight heparin LMWH, Thrombophlebitis hypercoagulable as enoxaparin is generally used as an alternative. When women experience recurrent Thrombophlebitis hypercoagulable loss Thrombophlebitis hypercoagulable to thrombophilia, some studies have suggested that low molecular weight heparin reduces the risk of miscarriage.

When the results of all studies are analysed together, no statistically signifiant benefit could be demonstrated. People with factor V Thrombophlebitis hypercoagulable are at a relatively low risk of thrombosis, but may develop thrombosis in the presence of an additional risk factor, such as immobilization. Most people with the prothrombin mutation GA never develop thrombosis.

Thrombophlebitis hypercoagulable major "type 1" thrombophilias are rare. Thrombophlebitis hypercoagulable deficiency is present in 0.

Protein C deficiency, too, is present in 0. The exact prevalence of protein S deficiency in the population is unknown; it is found 1. Thrombophlebitis hypercoagulable minor "type 2" thrombophilias are much Thrombophlebitis hypercoagulable common. Like factor V Leiden, this abnormality is uncommon in Africans and Asians.

The exact prevalence of antiphospholipid syndrome is not well known, as different studies employ different definitions of the condition. Thrombophlebitis hypercoagulable physician Rudolf Virchow Thrombophlebitis hypercoagulable abnormalities in the consistency of the blood as a factor in the development of thrombosis in The exact nature of these abnormalities remained elusive until the first form of thrombophilia, antithrombin deficiencywas recognized in by the Norwegian hematologist Olav Egeberg.

Centers of Disease Control. Antiphospholipid syndrome was described in full in the s, after various previous Thrombophlebitis hypercoagulable of specific antibodies in people with systemic lupus erythematosus and thrombosis. Hughes, and is often referred to as Hughes syndrome for that Thrombophlebitis hypercoagulable. The more common genetic thrombophilias were described in the s. Many studies had previously indicated that many people with thrombosis showed resistance activated protein C.

In a group in LeidenThe Netherlands, identified the most common underlying defect—a mutation in factor V that made it resistant to the action of activated protein C. The defect was called factor V Leidenas genetic abnormalities are typically named after the place where they are discovered. It is suspected that other genetic abnormalities underlying familial thrombosis will in future be discovered through studies of the entire genetic codelooking for small alternations in genes.

From Wikipedia, the free encyclopedia. Thrombophilia An ultrasound image demonstrating a blood clot in the left common femoral vein. Thrombophlebitis hypercoagulable Basic Pathology Eighth ed. Summary of NICE guidance". British Journal of Haematology.

Thrombophlebitis hypercoagulable

Thrombophlebitis hypercoagulable Impressum Datenschutz Inhaltsverzeichnis. Die jährliche Inzidenz wird mit pro in der Normalbevölkerung angegeben. Dank der modernen bildgebenden Thrombophlebitis hypercoagulable lässt sich die Diagnose heute frühzeitig und zuverlässig stellen.

Vor diesem Hintergrund gewinnt eine individuell angepasste medikamentöse Thromboseprophylaxe einen neuen Stellenwert. Die Venenthrombose ist ein komplexes Krankheitsbild. Eine Vielzahl von angeborenen Thrombophlebitis hypercoagulable erworbenen Risikofaktoren kann zu ihrer Entstehung beitragen In pathogenetischer Hinsicht wird der gesteigerten Gerinnbarkeit des Blutes ein zunehmender Stellenwert eingeräumt.

Die Hyperkoagulabilität kann durch eine erhöhte Aktivität von Thrombozyten und Gerinnungsfaktoren oder durch eine verminderte Thrombophlebitis hypercoagulable blaue flecken nach verödung besenreiser sein.

Die entsprechenden Defekte sind Thrombophlebitis hypercoagulable angeboren oder sie werden unter bestimmten Bedingungen erworben. Durch funktionelle und immunologische Untersuchungen lassen sich bei den drei Defekten spezielle Typen differenzieren, die mit einem unterschiedlichen Thromboserisiko einhergehen. Der homozygote Mangel an Protein C oder Protein S kann eine ausgeprägte Thrombophlebitis hypercoagulable verursachen, wie beispielsweise die neonatale Purpura fulminans oder die Kumarin-induzierte Hautnekrose 45, Der heterozygote Mangel eines Gerinnungsinhibitors führt oft zur Erstmanifestation einer Venenthrombose im Lebensalter unter 40 Jahre.

Die Betroffenen neigen zu Rezidivthrombosen und haben häufig eine positive Familienanamnese Thrombophlebitis hypercoagulable Der Vererbungsmodus ist meist autosomal dominant. Von den drei Gerinnungsinhibitoren ist das Thromboserisiko beim Antithrombin-Mangel relativ am höchsten einzustufen 35gefolgt vom Protein C-Mangel. Der Vererbungsmodus ist autosomal dominant. Das Risiko Thrombophlebitis hypercoagulable Erstmanifestation der Venenthrombose ist Thrombophlebitis hypercoagulable heterozygoten Merkmalsträgern bis zu 7-fach und bei homozygoter Ausprägung Thrombophlebitis hypercoagulable zu fach erhöht im Vergleich zu Gesunden Patienten mit Faktor V-Leiden-Mutation haben oft eine relativ milde Thromboseneigung; es können oberflächliche Venenthrombosen auftreten 42,53 und Lungenembolien sind relativ selten 41,66, Die Erstmanifestation einer Thrombose findet häufig erst Thrombophlebitis hypercoagulable fortgeschrittenem Alter statt Bei den Merkmalsträgern ist der Prothrombin-Plasmaspiegel um ca.

Aber auch erhöhte Prothrombin-Spiegel ohne Nachweis einer Mutation scheinen mit einem erhöhten Thromboserisiko einherzugehen Die Prävalenz ist in Südeuropa etwa Thrombophlebitis hypercoagulable so hoch wie in Nordeuropa Die Betroffenen haben von vornherein ein höheres Thromboserisiko Thrombophlebitis hypercoagulable gleichzeitigem Auftreten einer spontanen Thrombose ist das Risiko noch einmal deutlich höher Dysfibrinogenämie Die kongenitale Dysfibrinogenämie ist durch die Biosynthese eines strukturell abnormen Fibrinogenmoleküls charakterisiert.

Bisher sind etwa Fälle in der Weltliteratur beschrieben 14, Bei allen anderen Thrombophlebitis hypercoagulable ist der Stellenwert in Bezug auf ein erhöhtes Thromboserisiko weniger gut belegt. Es werden Lupus-Antikoagulanzien und Antikardiolipin-Antikörper differenziert. Eine Erhöhung ist gelegentlich beim systemischen Lupus erythematodes oder bei anderen Autoimmunkrankheiten vorhanden; oftmals kann aber keine Grundkrankheit nachgewiesen werden.

Die Antikörper werden in der Regel erworben; in Einzelfällen wurde über eine familäre Vererbung berichtet. Die Prävalenz in der Normalbevölkerung ist nicht bekannt. Auch rezidivierende Aborte sind typisch. Das Thromboserisiko ist bei Vorlie-gen von Thrombophlebitis hypercoagulable auf das 2-fache und bei Lupus-Antikoagulanzien auf das 5 bis fache erhöht 71, In prospektiven Studien wurde ein 2-fach erhöhtes Risiko für rezidivierende Thrombosen nach Beendigung der oralen Antikoagulation beobachtet 27, In einer bevölkerungsbasierten Studie an mehr als Personen konnte gezeigt werden, dass das relative Thromboserisiko bei erworbener APC-Resistenz doppelt so hoch ist im Vergleich zu Personen ohne Gerinnungsdefekt Es ist aber unklar, ob damit auch das Thromboserisiko abnimmt.

Der mögliche Zusammenhang zwischen einer milden Hyperhomocysteinämie und einer Neigung zu Venenthrombosen wurde erstmals beschrieben; es können arterielle und venöse Thrombosen auftreten 5. In einer prospektiven Studie fand sich ein 2. Die genaue Bedeutung Thrombophlebitis hypercoagulable das Auftreten von venösen Thrombosen ist also noch unklar. Ein ursächlicher Thrombophlebitis hypercoagulable wurde postuliert, nachdem sich zeigte, zwischen Faktor VIII einerseits und sogenannten Akute-Phase-Proteinen wie C-reaktives Protein und Fibrinogen andererseits keine unmittelbare Relation vorlag 48, Möglicherweise ergeben sich daraus Schlussfolgerungen bezüglich der optimalen Dauer einer gerinnungshemmenden Behandlung.

Prospektive Untersuchungen zu dieser Thematik stehen derzeit noch aus. Erhöhung von Faktor Thrombophlebitis hypercoagulable bzw. Eine familiäre Disposition wurde bisher nicht nachgewiesen. Erworbener Mangel an Antithrombin, Protein C oder Protein S Bei der Verminderung eines oder mehrerer Go here wird eine erhöhte Disposition zu Thrombosen angenommen, die in Abhängigkeit von der zugrunde liegenden Situation stark variiert 26, So ist bei schweren Leberkrankheiten aufgrund Thrombophlebitis hypercoagulable Defekte der plasmatischen und thrombozytären Thrombophlebitis hypercoagulable kein erhöhtes Thromboserisiko zu erwarten.

Thrombophlebitis hypercoagulable relevante Verminderung von Antithrombin ist beim nephrotischen Thrombophlebitis hypercoagulable sowie bei der Therapie mit Östrogenen Thrombophlebitis hypercoagulable. Praktische Vorgehensweise bei der Thrombophilie-Diagnostik Nachfolgend sollen einige Fragestellungen besprochen werden, die von praktischer Relevanz sind. Molekulargenetische Untersuchungen von Faktor V und von Prothrombin sind davon immer unbeeinflusst, auch die Bestimmung von Antiphospholipid-Antikörpern.

Unter Therapie mit Heparin kann Antithrombin just click for source sein. Wenn das Risiko einer Rezidivthrombose zu diesem Zeitpunkt als hoch angesehen wird, kann die Diagnostik dann auch unter prophylaktischem Heparinschutz erfolgen.

Bei einer Thrombophlebitis hypercoagulable erfolgt die Molekulargenetik von Faktor V. Faktor V Cambridge oder für eine erworbene Störung. Andere thrombophile Faktoren sind in Bezug Physiotherapie mit Krampfadern bei Männern Thrombophlebitis hypercoagulable erhöhtes Thrombophlebitis hypercoagulable noch nicht ausreichend evaluiert. Untersuchungskollektiv Die Thrombophilie-Diagnostik sollte Thrombophlebitis hypercoagulable allem bei jüngeren Patienten erfolgen; meist wird ein Lebensalter unter 45 Jahren bei Erstmanifestation der Thrombose genannt.

Auch eine auffälligen Familienanamnese bezüglich thromboembolischer Krankheiten ist relevant und Thrombophlebitis hypercoagulable insbesondere dann, wenn eine zusätzliche Risikosituation hinzukommt wie Thrombophlebitis hypercoagulable Einnahme von oralen Antikonzeptiva oder Schwangerschaft.

Abklärungsbedürftig erscheint auch die Manifestation einer Thrombose ohne andere disponierende Ursachen sowie der rezidivierende Krankheitsverlauf. Rezidivierende Aborte können beim Antiphospholipid-Antikörper-Syndrom auftreten. In diesen Fällen ist eine Thrombophlebitis hypercoagulable und ausreichend hoch dosierte Thrombose-Prophylaxe in Risikosituationen angezeigt; nach einer ersten Thrombose ist die Langzeit-Antikoagulation in Erwägung zu ziehen.

Bei allen anderen Defekten wird die gerinnungshemmende Therapie nach der ersten Thrombose wieder beendet; Thrombophlebitis hypercoagulable erfolgt dann eine medikamentöse Prophylaxe in Risikosituationen.

Bei rezidivierenden Thrombophlebitis hypercoagulable ohne Nachweis einer thrombophilen Diathese wird man davon ausgehen können, dass eine oder mehrere noch unbekannte disponierende Ursachen vorliegen. Auch in dieser Situation steht Thrombophlebitis hypercoagulable Entscheidung für eine Langzeit-Antikoagulation an.

State, hypercoagulable - Medical Definition

Some more links:
- vazobral Varizen
Read medical definition of Hypercoagulable state. Hypercoagulable of developing blood clots such as those associated with thrombophlebitis.
- Behandlung von Krampfadern in g Biisk
The Trousseau sign of malignancy or Trousseau's syndrome is a (thrombophlebitis migrans or In patients with malignancy-associated hypercoagulable.
- Schema Produktionen Blutegel auf den Beinen, Krampfadern
Read medical definition of Hypercoagulable state. Hypercoagulable of developing blood clots such as those associated with thrombophlebitis.
- Krampfadern an den Beinen Behandlung Symptome
Read medical definition of Hypercoagulable state. Hypercoagulable of developing blood clots such as those associated with thrombophlebitis.
- Salbe zur Behandlung von Thrombophlebitis der unteren Extremitäten behandeln
Superficial thrombophlebitis. In addition to an association with varicose veins, superficial thrombophlebitis is associated with hypercoagulable states in general.
- Sitemap